ASTRAZENECA WKN: 886455 ISIN: GB0009895292 Kürzel: AZN Forum: Aktien Thema: Hauptdiskussion

🤣

🤦🏻‍♂️

18 September 2021 Updated results from the CASPIAN Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.

Hier gibt es fast nur noch posts von Oxana, schon seltsam. Hast nix besseres zu tun ?

18 September 2021 Detailed positive results from the head-to-head DESTINY-Breast03 Phase III trial showed that Enhertu (trastuzumab deruxtecan), the AstraZeneca and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), demonstrated superior progression-free survival (PFS) versus trastuzumab emtansine (T-DM1), a HER2-directed ADC currently approved to treat patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. Results were presented today in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2021.

18 September 2021 Detailed primary results from the positive Phase II DESTINY-Lung01 trial of Enhertu (trastuzumab deruxtecan), the AstraZeneca and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), showed a robust and durable tumour response in previously treated patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC). Results presented during a late-breaking Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress 2021 and simultaneously published in The New England Journal of Medicine confirm Enhertu as the first HER2-directed therapy to show a strong tumour response in this patient population.

17 September 2021 Detailed results from the positive Phase II DESTINY-Gastric02 trial showed that Enhertu (trastuzumab deruxtecan), the AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), provided a clinically meaningful and durable tumour response in patients with HER2-positive metastatic and/or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with a trastuzumab-containing regimen. Results were presented during a late-breaking mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021.

17 September 2021 Results from the large, randomised COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with Imfinzi (durvalumab) improved progression-free survival (PFS) and objective response rate (ORR) compared to Imfinzi alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).

Bin hier auch gut und gerne investiert, aber wenn es schon mal um die Gesundheit geht, news von cnbc: Im August fand eine britische Studie mit mehr als einer Million vollständig geimpften Personen heraus, dass der Schutz sowohl vor dem Oxford-AstraZeneca- als auch dem Pfizer-BioNTech-Impfstoff mit der Zeit nachließ. Einen Monat nach Erhalt einer zweiten Dosis des Pfizer-Impfstoffs lag der Schutz vor dem Virus bei 88%, wie die Analyse ergab. Nach fünf bis sechs Monaten sank dieser Schutz auf 74 %. Der Schutz lag nach der vollständigen Impfung mit dem Oxford-AstraZeneca-Impfstoff monatlich bei 77 % und sank nach vier bis fünf Monaten auf 67 %.

3 September 2021 07:00 BST Approval based on interim results from Phase III trial demonstrating complete terminal complement inhibition with reduced dosing frequency compared to Soliris

Ultomiris approved in the EU for children and adolescents with paroxysmal nocturnal haemoglobinuria

„In clinical trials, Vaxzevria demonstrated 100% efficacy against severe disease and hospitalisation after two doses.1,2 Real-world evidence shows the vaccine is around 90% or higher effective against WHO-identified variants of concern.3 Vaxzevria has been shown to be generally well tolerated. Incidents of thrombosis with thrombocytopenia (TTS) have been reported in a small number of people. Early diagnosis allows appropriate treatment of these events4,5 and there is no elevation of the risk of TTS at the second dose, compared to the rates expected in the general population.6 „

Astrazeneca wird nur schlecht geredet… habt ihr mal über eine Booster Dosis nach 2x Astra-Impfung gehört? Ich lese nur über Nachlass der Immunität nach mRNA Impfungen.